- Novavax earned a $125 million milestone payment following the start of Sanofi's Phase 3 flu-COVID combo vaccine trial in Europe.
- Potential for additional $300 million in development/launch milestones plus sales royalties under the collaboration agreement.
- Substantially improves Novavax cash runway and validates late-stage pipeline progress.
?? Positive AI Sentiment (+6.8 / 10)